10-Q/A: Dalrada Financial Reports Deepening Losses and Going Concern Doubts Amidst Restated Q2 Financials

Dalrada Financial Corporation filed an amended quarterly report revealing a significant increase in net losses and a worsening working capital deficit, raising substantial doubt about its ability to continue as a going concern.

Summary

• Dalrada Financial Corporation filed an amended Form 10-Q/A to correct its revenue and accounts receivable for the fiscal quarter ended December 31, 2023.
• The company reported a net loss of $6,996,276 for the three months ended December 31, 2023, compared to a net loss of $4,482,165 for the same period in 2022, representing a 56.1% increase in loss.
• For the six months ended December 31, 2023, the net loss was $11,834,412, a 54.6% increase from the $7,652,341 net loss in the prior year period.
• Total revenues for the six months ended December 31, 2023, slightly decreased to $9,375,396 from $9,510,887 in the comparable prior year period.
• Gross profit significantly declined to $1,416,522 for the six months ended December 31, 2023, from $4,199,427 in the prior year, primarily due to an increase in lower-margin pharmaceutical sales within the Genefic segment.
• The company's working capital deficit worsened to $2,681,448 as of December 31, 2023, from $202,420 as of June 30, 2023, mainly due to increased accounts payable to fund payroll and outstanding vendors.
• Accounts payable and accrued liabilities to related parties surged to $5,029,683 as of December 31, 2023, from $547,949 as of June 30, 2023.
• Cash and cash equivalents decreased to $598,438 as of December 31, 2023, from $812,806 as of June 30, 2023.
• The company's disclosure controls and procedures were deemed not effective as of December 31, 2023.
• The company's OTC Markets status changed to the Expert Market on January 15, 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by significantly increased net losses, a worsening working capital deficit, and an explicit 'going concern' warning. Reliance on related party financing and ineffective internal controls further compound the negative outlook, despite some segment-specific revenue increases.

Positives

• Net cash used in operating activities decreased to $3,476,354 for the six months ended December 31, 2023, from $4,911,404 in the prior year, primarily due to a reduction in accounts receivable related to the COVID-19 business and reduced inventory purchases.
• Genefic segment revenue increased by 5.8% to $4,683,496 for the six months ended December 31, 2023, driven by a material rise in Genefic Specialty Pharmacy sales.
• Dalrada Precision Manufacturing segment's loss from operations significantly decreased to $(302,425) for the six months ended December 31, 2023, from $(1,623,362) in the prior year, attributed to increased margins for Precision Parts sales and decreased legal and professional fees.

Negatives

• Net loss increased by 56.1% for the three months and 54.6% for the six months ended December 31, 2023, compared to the prior year periods.
• Gross profit for the six months ended December 31, 2023, decreased by 66.2% to $1,416,522 from $4,199,427 in the prior year.
• Working capital deficit worsened significantly to $2,681,448 as of December 31, 2023, from $202,420 as of June 30, 2023.
• Accounts payable and accrued liabilities to related parties increased by over $4.4 million, indicating a growing reliance on related party funding for operational expenses.
• Cash and cash equivalents declined by 26.4% from June 30, 2023, to December 31, 2023.
• Dalrada Climate Technology segment's revenue decreased by 12.7% and shifted from a profit to a significant loss from operations.
• Dalrada Technologies segment's revenue decreased by 39% due to completing customer contracts without securing larger new ones.
• The company's disclosure controls and procedures were found to be ineffective, indicating a material weakness in financial reporting oversight.

Risks

• The company's continuation as a going concern is dependent on continued financial support from related parties, ability to identify future investment opportunities, obtain necessary debt or equity financing, and generate profitable operations.
• The company has incurred significant losses and has limited working capital, raising substantial doubt about its ability to meet future obligations.
• Reliance on related party financing poses a risk, as several related party notes are in default, and their continued support is critical.
• Ineffective disclosure controls and procedures increase the risk of material misstatements in financial reporting.
• Ongoing legal proceedings, including a suit for misappropriation of funds against a former joint venture partner and a judgment against a subsidiary, could result in further financial liabilities.
• The company's ability to obtain additional financing through private placements and/or public offerings is uncertain, and there is no assurance that such financing will be available on acceptable terms.
• Issuances of additional shares to fund operations will result in dilution to existing stockholders.
• The change in OTC Markets status to the Expert Market may reduce liquidity and investor interest in the company's stock.

Future Outlook

The company anticipates needing additional liquidity over the next twelve months to fund operations, expand subsidiaries, grow the COVID-19 testing segment, and continue commercialization of Likido heating & cooling units and Dalrada Energy Services. Management plans to support operations by raising capital and accelerating sales & marketing efforts for high-margin products and services.

Management Comments

• "Our net loss and limited working capital raise substantial doubt about our ability to continue as a going concern."
• "We will be required to raise substantial capital to fund our capital expenditures, working capital, and other cash requirements."
• "We will continue to rely on related parties and seek other financing to complete our business plans."
• "There is no assurance that we will be able to obtain additional financing through private placements and/or public offerings necessary to support our working capital requirements."

Industry Context

The document highlights Dalrada's diverse business divisions including healthcare (Genefic), climate technology, precision manufacturing, and general technology. The performance varies across segments, with Genefic's pharmaceutical sales showing growth but at lower margins, and climate technology experiencing reduced activity in a key project. The company's focus on clean energy, health care, and technology aligns with broader market trends, but its financial performance indicates significant internal challenges in capitalizing on these opportunities.

Comparison to Industry Standards

• The company's significant net losses and negative working capital position are substantially below industry averages for healthy, growing companies.
• The reliance on related party financing and the explicit 'going concern' warning indicate a financial instability that is not typical for established public companies.
• The reported ineffectiveness of disclosure controls and procedures suggests a lack of robust internal governance compared to industry best practices, which prioritize strong financial controls for investor confidence.

Management Changes

Corporate Governance

Legal Proceedings

• Dalrada Health Products filed a lawsuit against Vivera Pharmaceuticals, Inc. and its CEO, Paul Edalat, for misappropriation of funds totaling $2,104,509 on behalf of the joint venture, Pala Diagnostics. The case is stayed until a valuation for Pala Diagnostics is completed for dissolution.
• Likido Ltd. was ordered to pay $429,987 in damages, $42,374 in legal costs, and $19,754 in arbitration fees to MAPtech PACKAGING LIMITED, plus 8% annual interest, following a concluded dispute.

Related Party Transactions

• Accounts payable and accrued liabilities to related parties increased significantly to $5,029,683 as of December 31, 2023, from $547,949 as of June 30, 2023, primarily due to payroll-related expenditures.
• The company received cash funding or had expenses paid on its behalf from related parties totaling $1,854,380 for the six months ended December 31, 2023.
• Related party notes payable increased to $4,834,971 as of December 31, 2023, from $1,900,083 as of June 30, 2023.
• Several related party notes are in default, but the company has not received notices of default or demands for payment.
• Related parties are corporations owned and/or operated by an individual with a familial relationship to the company's CEO.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity issuances to raise capital.
• Shareholders are experiencing a substantial accumulated deficit, indicating a significant erosion of equity value.
• Employees and suppliers may face increased uncertainty regarding the company's long-term stability due to the 'going concern' warning and worsening financial position.
• Creditors, particularly related parties, are exposed to increased default risk given the company's financial distress and the default status of some notes.

Next Steps

• Raise substantial capital through debt or equity financing to fund operations and business plans.
• Accelerate sales and marketing efforts for high-margin heating & cooling units, precision parts, Dalrada Energy Services, DepTec's deposition systems, and COVID-19 testing.
• Address the identified material weakness in disclosure controls and procedures.
• Continue efforts to resolve legal proceedings, including the valuation and dissolution of Pala Diagnostics and payment of damages to MAPtech.

Key Dates

Recommendation

Keywords

Dalrada Financial Corporation, DFCO, 10-Q/A, Quarterly Report, Restated Financials, Net Loss, Going Concern, Working Capital Deficit, Related Party Transactions, Healthcare, Climate Technology, Precision Manufacturing, Technology Services, SEC Filing, Internal Controls, Liquidity, Preferred Stock, Convertible Notes, Warrants